Epilepsy Trial, Recruiting (NCT05101161)

Epilepsy Trial, Recruiting NCT05101161 Sponsor: ETH Zurich Condition: Epilepsy

Printed from Voxsanity (voxsanity.com.au) — NCT05101161 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Epilepsy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 or older who are already scheduled to receive a Percept™ PC neurostimulator device as part of their standard medical care
People who are expected to stay in hospital for at least 3 days after the operation

Who may not be able to join:

People whose doctors expect them to survive less than 1 year
People who are not fully alert or aware (for example, those with a reduced level of consciousness)
People who are unable to communicate, including difficulties with hearing, seeing, speaking, or understanding
People with other serious health conditions at the same time, such as heart or infectious diseases, or those who need to be kept in isolation
People who would be unable to follow the study procedures
People who do not have sufficient knowledge of the language the study is conducted in
People who are unable to give their informed consent to take part
People who are considered unlikely to follow the study protocol throughout the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Oliver Bichsel, MD, MSc ETH, ETH Zurich

Phone: +41 44 510 72 34

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05101161

Sponsor: ETH Zurich

Phase: Not Applicable

Status: Recruiting

Condition: Epilepsy

Trial contact: +41 44 510 72 34

More information: https://clinicaltrials.gov/study/NCT05101161

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 or older who are already scheduled to receive a Percept™ PC neurostimulator device as part of their standard medical care
People who are expected to stay in hospital for at least 3 days after the operation

Who may not be able to join:

People whose doctors expect them to survive less than 1 year
People who are not fully alert or aware (for example, those with a reduced level of consciousness)
People who are unable to communicate, including difficulties with hearing, seeing, speaking, or understanding
People with other serious health conditions at the same time, such as heart or infectious diseases, or those who need to be kept in isolation
People who would be unable to follow the study procedures
People who do not have sufficient knowledge of the language the study is conducted in
People who are unable to give their informed consent to take part
People who are considered unlikely to follow the study protocol throughout the trial

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

ETH Zurich

Registry

ClinicalTrials.gov

Start date

23 September 2021

Est. completion

23 September 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Amount of endogenous neuromodulation (difference in oscillatory power)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov